Open Access

MicroRNA‑223‑induced inhibition of the FBXW7 gene affects the proliferation and apoptosis of colorectal cancer cells via the Notch and Akt/mTOR pathways

  • Authors:
    • Zhixin Liu
    • Teng Ma
    • Jufeng Duan
    • Xiaofei Liu
    • Long Liu
  • View Affiliations

  • Published online on: December 20, 2020     https://doi.org/10.3892/mmr.2020.11793
  • Article Number: 154
  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The tumour suppressor gene F‑box and WD repeat domain‑containing 7 (FBXW7) plays an important role in human cancer by regulating cell division, proliferation and differentiation. However, the exact regulatory mechanisms of microRNA (miR)‑223 in colorectal cancer (CRC) cells are still unknown. The present study aimed to investigate the effect and mechanism of miR‑223 inhibiting FBXW7 on the proliferation and apoptosis of CRC cells. HCT116 cells were transfected with miR‑223 mimics or small interfering RNA (siRNA) targeting FBXW7 (siFBXW7), and the effects of these treatments on cell proliferation and apoptosis were examined. The downstream Notch and Akt/mTOR pathways were also assessed. Following miR‑223 overexpression, the mRNA and protein expression levels of FBXW7 were downregulated. Transfection with miR‑223 mimics or siFBXW7 promoted the proliferation of HCT116 cells and inhibited apoptosis by promoting the Notch and Akt/mTOR signalling pathways. Conversely, miR‑223 mimics transfection with FBXW7 overexpression inhibited cell viability and restored apoptosis. Thus, the present study demonstrated that miR‑223 could bind to the FBXW7 gene and inhibit its expression, ultimately increasing the proliferation and preventing the apoptosis of CRC cells through the Notch and Akt/mTOR signalling pathways.

Introduction

Colorectal cancer (CRC) is the third most common malignant tumour in China, and its mortality ranks fourth among all malignant tumours (1,2). At present, the first choice of treatment for CRC is surgical resection. However, the optimal time window for surgery is often missed when the early symptoms of CRC are not detected; thus, early screening for the diagnosis of CRC is key to improving treatment outcomes (3). Identifying a marker that is specific to CRC and easy to detect would provide new insight for the early diagnosis, treatment and monitoring of CRC.

F-box and WD repeat domain-containing 7 (FBXW7) is a novel ubiquitin ligase encoded by the tumour suppressor gene FBXW7. Its active targets consist of a variety of cancer-related factors, such as cyclin E, c-Myc, Mcl-1, c-Jun and mTOR (4,5). Abnormal expression of these targets is associated with CRC, gastric cancer and ovarian cancer (6). FBXW7 plays a role in physiological and pathological processes, such as tumour cell proliferation, early apoptosis and signal transduction (7,8). Previous studies have indicated that the expression of FBXW7 serves an indispensable role in the occurrence, development and metastasis of CRC (911).

MicroRNAs (miRNAs/miRs) are involved in a wide range of cellular functions and normal biological processes, including cell proliferation, differentiation, apoptosis and biotic stress resistance (12,13). Notably, some miRNAs are considered to have oncogenic activities, while others act as tumour suppressors (14,15). Oncogenic miRNAs are upregulated in cancer and promote cancer development by targeting tumour suppressor genes through different mechanisms. For instance, previous studies have identified a negative correlation between miR-223 expression and FBXW7 expression in breast cancer, hepatocellular carcinoma, non-small cell lung cancer and CRC (1619). Monitoring miRNAs that bind to the FBXW7 gene, and regulate CRC development and progression, could be an important approach for the prognosis of clinical treatment effects. However, the precise regulatory mechanisms underlying the effects of miR-223 on CRC progression remain unclear.

Notch signalling is an evolutionarily conserved pathway that is involved in various processes, including cell proliferation, differentiation and apoptosis (20). Notch signalling is also considered to be associated with tumorigenesis (21). Increasing evidence has revealed that Notch1 is relevant to other signalling pathways, such as Akt/mTOR and NF-κB signalling (22,23). In addition, miRNAs have been reported to regulate genes within the Notch and mTOR signalling pathways (24,25); therefore, the miR-223/FBXW7 axis may be associated with Notch/mTOR signaling.

The aim of the present study was to examine the regulatory relationship between miRNAs, FBXW7 and associated signalling pathways in order to improve current understanding of the mechanisms underlying CRC progression. The present study demonstrated that miR-223 was upregulated in CRC tissue and could bind to the 3′untranslated region (UTR) of the FBXW7 gene. miR-223 also promoted HCT116 cell proliferation, whilst inhibiting apoptosis.

Materials and methods

Clinical samples

A total of 20CRC primary tumour tissue samples and matched adjacent non-tumour tissues were collected at the Affiliated Renmin Hospital of Hubei University of Medicine (Shiyan, China) between October 2016 and December 2018. All patients were diagnosed in histopathologically and clinically according to the American Joint Committee on Cancer criteria, and performed surgical operation. The adjacent tissue was 5 cm away from the edge of the tumour, all the tissue samples were snap frozen using liquid nitrogen, and then stored at −80°C until further analysis. This research was approved by the Ethics Committee of Hubei University of Medicine, and all patients provided written informed consent for the use of samples.

Plasmid construction

The FBXW7 gene was cloned into pTriEx-1.1 vector. The 3′UTR of the FBXW7 gene was inserted into pMIR-REPORT vector (Ambion) to construct the recombinant plasmids for luciferase reporter gene assays. The primers used for PCR are listed in Table SI. The pTriEx-1.1 (Novagen) and pMIR-REPORT vectors were separately digested with HindIII/SacI or NcoI/BamHI, respectively, then the digested fragments were ligated with T4 DNA Ligase (New England Biolabs, Inc.) after purification. The recombinant plasmids were transformed into Escherichia coli and screened by PCR, and their sequences verified by sequencing.

Bioinformatics analysis

The potential miRNAs targeting the FBXW7 gene (including its UTR) were analysed by TargetScan (version 7.1; www.targetscan.org/). Target miRNA expression was predicted using miRanda (www.microrna.org/microrna/). The bioinformatics analyses, including expression and prognosis, were performed by Sangerbox (http://sangerbox.com/Tool) using the pan-cancer monogenic fast comprehensive analysis tool. The expression data of normal mucosa tissues and CRC tissues were obtained from Genotype-Tissue Expression (GTEx, http://gtexportal.org/home/) and The Cancer Genome Atlas (TCGA, http://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga). Differential gene expression levels was calculated as the log2 of its upper quartile Fragments Per Kilobase of transcript per Million mapped reads value. The expression levels of FBXW7 mRNA were calculated as the log2 of its TPM (transcripts per million) value after normalization of gene length and sequencing depth.

Immunohistochemistry staining

The procedures for immunohistochemistry staining were performed as previously reported (26). Sections (3-µm thick) were fixed using 4% paraformaldehyde for 12 h. The paraformaldehyde-fixed, paraffin-embedded sections were deparaffinized and rehydrated, and antigen retrieval was performed in boiling citrate buffer for 10 min, followed by blocking with 3% hydrogen peroxide for 10 min at room temperature. After washing with PBS three times, the sections were incubated with anti-FBXW7 antibody (1:200; Abcam; cat. no. ab109617) overnight at 4°C. The secondary antibody (1:50; Beyotime Institute of Biotechnology; cat. no. A0208) was incubated for 1 h at room temperature, followed by incubation with 3-diaminobenzidine (DAB) and re-staining with haematoxylin. The staining results were photographed under a BX46 light microscope (Olympus Corporation) and evaluated by two pathologists in a blinded manner.

Cell culture and transfection

The human HCT116 cell line was purchased from American Type Culture Collection and cultured in high-glucose DMEM (Thermo Fisher Scientific, Inc.) containing 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) in a 37°C incubator with 5% CO2. Cells in the logarithmic growth phase (80% confluence) were used for experiments. The 50 ng pMIR-REPORT luciferase reporter plasmids (Ambion; 50 ng), miR-223 mimics (5′-UGUCAGUUUGUCAAAUACCCCA-3′), miR mimic control (miCtr, 5′-UUCUCCGAACGUGUCACGUTT-3′), miR-223 inhibitor (5′-UGGGGUAUUUGACAAACUGACA-3′) and miR-223 inhibitor control (Ctr; 5′-CAGUACUUUUGUGUAGUACAA-3′) were transfected using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). Small interfering RNA (siRNA) targeting FBXW7 (siFBXW7−1, 5′-ACAGGACAGUGUUUACAAA-3′; siFBXW7−2, 5′-CCAUGCAAAGUCUCAGAAU-3′) and negative control (si-NC, 5′-UUCUCCGAACGUGUCACGUTT-3′) were transfected using Entranster™-R4000 (Engreen Biosystem, Ltd.), according to the manufacturer's instructions. All small nucleic acids were purchased from Shanghai GenePharma Co., Ltd. and were used at a final concentration of 20 nM. The cells were treated or collected at the indicated times after transfection.

Luciferase reporter gene assay

The 3′UTR sequences of FBXW7 were cloned into the pMIR-REPORT vector to construct the FBXW7 luciferase reporter plasmids. A total of 50 ng reporter plasmids were co-transfected with 20 nM miR-223 mimics, miR-25 mimics, miR-223 inhibitor and mimics control (miCtr) into 293T cells. Luciferase activity was measured 36 h later by fluorescence detection with the Luciferase Assay System (Promega Corporation). The cells in the plate were lysed with 5Xcell lysis reagent (Promega Corporation). After centrifugation, the supernatant was collected and added to 100 µl luciferase assay reagent at room temperature, and luciferase was measured using a Glomax 20/20 bioluminescence detector (Promega Corporation). The luciferase activity was normalized to the activity of Renilla luciferase.

Cellular viability assay

The viability of HCT116 cells was detected using a Cell Counting Kit-8 (CCK-8) kit (Dojindo Molecular Technologies, Inc.). CCK-8 reagent (10 µl/well) was added to 1×106 HCT116 cells/well at 0, 24, 48 and 72 h post-transfection, which were then incubated at 37°C with 5% CO2 for 2 h. The absorbance was measured in each well at a wavelength of 450 nm using the xMark Microplate Absorbance Spectrophotometer (Bio-Rad Laboratories, Inc.). Each group was set up in triplicate.

Apoptosis assay

HCT116 cells transfected with miR-223 mimics or inhibitor were analysed using an Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) Apoptosis Staining Kit (cat. no. ab14085; Abcam). A total of 1×106 HCT116 cells from each group were collected 48 h post-transfection. After washing twice with PBS, the cells were resuspended in 500 µl binding buffer, then mixed with 5 µl Annexin V-FITC followed by 5 µl PI and incubated in the dark for 10 min at room temperature. Apoptosis in each group was detected by flow cytometry (Beckman Coulter, Inc.; CytoFLEX), the frequency of apoptotic cells (Annexin V+PI+) was obtained using software CytExpert 2.4 (Beckman Coulter, Inc.). The experiment was independently repeated three times.

FBXW7 rescue assay

A total of 1×106 HCT116 cells/well were transfected with miR-223 mimics or NC using Entranster™-R4000 (Engreen Biosystem, Ltd.), then transfected with 1 µg pTriEx-FBXW7 overexpression plasmid or empty plasmid 12 h later. The cells were collected 48 h later and lysed for protein detection by western blotting. The cell viability was also detected at the indicated times following miR-223 transfection and apoptosis rates were detected by flow cytometry at 48 h post-transfection.

RNA extraction and reverse transcription-quantitative (RT-q)PCR

Total RNA was extracted from homogenised tissue samples or from HCT116 cells harvested 36 h after transfection using TRIzol® (Invitrogen; Thermo Fisher Scientific, Inc.). cDNA was obtained using a OneScript cDNA Synthesis kit (Applied Biological Materials Inc., cat. no. G594) with an oligo(dT) primer or miRNA-specific stem-loop primers, according to manufacturer's protocol. The primers for RT and qPCR are listed in Table SI. mRNA expression levels were examined on an CFX96 Touch PCR system (Bio-Rad Laboratories, Inc.) using SYBR Premix Ex Taq™ (Applied Biological Materials Inc., G892). The thermocycling conditions were as follows: 95°C for 30 sec, followed by 40 cycles at 95°C for 5 sec and 60°C for 30 sec. GAPDH or U6 were used as the internal reference for genes or miRNAs, respectively. Each reaction was set up in triplicate, and experiments were performed three times. The relative expression of each target was analysed using the 2−ΔΔCq method (27).

Western blot analysis

Total proteins of each group were collected from HCT116 cells 48 h post-transfection or from homogenised tissue and lysed using RIPA reagent (Solarbio), then quantified using a BCA kit (Beyotime Institute of Biotechnology). Proteins were separated by SDS-PAGE on 10% gels and transferred to PVDF membranes (Bio-Rad Laboratories, Inc.). The membranes were then blocked at 37°C for 1 h using 5% skimmed milk and incubated at 4°C overnight with mouse or rabbit anti-human polyclonal antibodies specific for FBXW7 (1:2,000; ProteinTech Group, Inc.; cat. no. 28424-1-AP), Notch intracellular receptor domain (NICD; 1:500; GeneTex, cat. no. GTX28925), hes family bHLH transcription factor 1 (Hes-1; 1:1,000; GeneTex; cat. no. GTX108356) and phosphorylated (p)-mTOR (1:1,000; GeneTex; cat. no. GTX132803). Antibodies specific for Akt (cat. no. 10176-2-AP), p-Akt (cat. no. 66444-1-Ig), mTOR (cat. no. 66888-1-Ig, ProteinTech Group, Inc.) was used at 1:2,000 dilution, and the mouse anti-human GAPDH monoclonal antibody was used at a 1:5,000 dilution (Beyotime Institute of Biotechnology; cat. no. AF5009). After washing the membrane three times, goat anti-mouse (cat. no. A0216) or anti-rabbit IgG (cat. no. A0208) (both at 1:5,000 dilution; Beyotime Institute of Biotechnology) was added, and the mixture was incubated for 1 h at room temperature, and then subjected to imaging using an ECL solution (Beyotime Institute of Biotechnology). Densitometric analysis of the protein bands was carried out using Image Lab 3.0 (Bio-Rad Laboratories, Inc.). Protein expression levels are presented as the ratio of the densitometric value of target proteins relative to the GAPDH internal control.

Statistical analysis

The cell viability, apoptosis and RT-qPCR results were statistically analysed using GraphPad Prism 5.0 software (GraphPad Software, Inc.). The data are presented as the mean ± SD of three independent experimental repeats. Comparisons between multiple groups were analysed using one-way ANOVA followed by the Tukey's HSD post hoc test. Student's t-test was used to compare two groups. P<0.05 was considered to indicate a statistically significant difference.

Results

Downregulation of FBXW7 expression in CRC

First, the present study investigated the difference in FBXW7 expression in datasets from TCGA and GTEx databases representing 27 types of tumour tissue and adjacent normal tissue samples (Fig. 1A). FBXW7 expression was significantly downregulated in most tumour types, compared with adjacent tissue. Moreover, the expression of FBXW7 was evaluated in CRC tissue samples and adjacent normal tissue (n=20). The mRNA expression levels of FBXW7 in CRC tissue were significantly lower than in normal tissues (Fig. 1B). The protein expression of FBXW7 was also lower in CRC tissues compared with in adjacent tissues (Fig. 1C and D). Immunohistochemical staining also suggested reduced expression in the cells of CRC tissue compared with in adjacent colon tissue (Fig. 1E). Disease-specific survival (DSS) and overall survival (OS) time of patients with CRC did not correlate with FBXW7 expression (Figs. S1 and S2).

Upregulated miR-223 targets FBXW7 in CRC cells

miRNA sequences complementary to the human FBXW7 gene were predicted using the TargetScan and miRanda (28) tools, which suggested miR-223, miR-22 and miR-25 targeted the 3′UTR of FBXW7 (Fig. 2A). To determine the expression levels of the predicted miRNAs in CRC cells, the levels of miRNAs in HCT116 cells were measured using RT-qPCR. The relative expression level of miR-223 was significantly increased in CRC tissue compared with in adjacent tissues (Fig. 2B).

miR-223 binds to FBXW7 and inhibits its expression in HCT116 cells

A FBXW7 luciferase vector was co-transfected with miR-223 mimics, miR-25 mimics, miCtr or miR-223 inhibitor into 293T cells. Changes in luciferase activity in the transfected cells were measured 36 h post-transfection. miR-223 significantly reduced relative luciferase activity, while miR-25 did not influence luciferase activity (Fig. 3A). This indicates that miR-223 may interact with the 3′UTR of FBXW7. The effect of miR-223 on the expression of FBXW7 was evaluated in HCT116 cells. miR-223 mimics or inhibitor were used to transfect HCT116 cells (Fig. 3B). FBXW7 protein expression levels were decreased after transfection with miR-223 mimics compared with miCtr (Fig. 3C). mRNA expression levels were also significantly downregulated (Fig. 3C). However, FBXW7 protein and mRNA expression levels were not significantly altered after transfection with the inhibitor. This indicated that miR-223 could directly inhibit FBXW7 expression.

Inhibition of FBXW7 by miR-223 affects the proliferation and apoptosis of HCT116 cells

To investigate the function of miR-223 targeting FBXW7 in CRC cells, HCT116 cells were transfected with miR-223 mimics or inhibitor sequences, and cell viability was evaluated at different time points. Transfection with miR-223 mimics increased cell proliferation after transfection for 48 h, compared with miCtr (Fig. 4A). However, transfection with the inhibitor had no effect. In addition, apoptosis of HCT116 cells was detected by flow cytometry (Fig. 4B). Transfection with miR-223 mimics led to a decrease in the number of apoptotic cells, compared with miCtr, whereas the miR-223 inhibitor promoted apoptosis of HCT116 cells, compared with Ctr (Fig. 4C).

siRNA silencing of FBXW7 regulates HCT116 cell proliferation and apoptosis

siRNA targeting FBXW7 expression was used to further verify the effect of FBXW7 on HCT116 cell proliferation and apoptosis. Compared with si-NC, the relative mRNA and protein expression levels of FBXW7 were reduced after transfection with siFBXW7-1 and siFBXW7-2 (Fig. 5A and B). The cell viability assay indicated that siFBXW7-2 increased HCT116 cell proliferation, compared with si-NC (Fig. 5C). Moreover, compared with the control, both siRNA transfections reduced the apoptotic cell rate (Fig. 5E). In addition, rescuing FBXW7 through overexpression after transfection with miR-223 mimics inhibited cell viability and increased apoptosis compared with miR-223 mimics alone (Fig. 5D and G). FBXW7 protein levels were upregulated following co-transfection with FBXW7 overexpression vector and miR-223 mimics, compared with mimics alone (Fig. 5F). Altogether, these results indicated that miR-223 may promote the proliferation and suppress the apoptosis of HCT116 cells by targeting FBXW7.

FBXW7 functions through the Notch and Akt/mTOR pathways

Multiple studies have demonstrated that FBXW7 plays a key role in cancer by regulating the Notch and mTOR pathways (29,30). Thus, the possible association between miR-223/FBXW7 axis and Notch-mTOR signalling pathways was examined. Following transfection with miR-223 mimics or siFBXW7−2, the mRNA expression levels of Notch and its target gene Hes-1 were increased, compared with miCtr + si-NC group (Fig. 6A and B), and the expression levels of NICD and Hes-1 were increased after inhibition of FBXW7 (Fig. 6C). The protein expression levels of total mTOR and p-mTOR, as well as the upstream components of the mTOR pathway, Akt and p-Akt were also examined (Fig. 6D). Transfection with miR-223 mimics and siFXBW7−2 both increased the ratio of p-mTOR to total mTOR and the ratio of p-Akt to total Akt (Fig. 6F). In addition, the expression level of Bcl-2 was also upregulated following FBXW7 downregulation either through miR-223 mimics or siFXBW7−2, while the levels of Bax were downregulated (Fig. 6E), and the ratio of Bax to Bcl-2 was decreased (Fig. 6F). These results demonstrated that FBXW7 functioned through the Notch and Akt/mTOR signalling pathways.

Discussion

The tumour suppressor gene FBXW7 has been reported to inhibit tumour progression by suppressing cell proliferation and inducing apoptosis (31,32). FBXW7 may be an independent factor affecting the survival of patients with CRC, and its expression has been reported to be associated with the occurrence, development and prognosis of CRC (33,34). Iwatsuki et al (35) detected the expression levels of FBXW7 mRNA and protein in 93 CRC samples and found that the expression of FBXW7 was lower in CRC tumour tissues than in adjacent tissue samples. Notably, patients with low expression of FBXW7 had a poor prognosis (35).

miR-223 is significantly associated with the tumour size and TNM stage of gastric cancer, as well as the invasion and distant metastasis of CRC (36,37). Therefore, miR-223 may have a role in the development of CRC, similar to miR-200a and miR-125b (38,39). FBXW7 is one of the identified targets of various miRNAs (40,41). Sano et al (42) demonstrated that miR-25 could downregulate the expression of FBXW7, which may affect the proliferation, invasion and apoptosis of gastric cancer cells. In addition, a previous study confirmed that miR-25 and miR-223 could reduce the mRNA expression levels of FBXW7, which affects the activity of cyclin E and cell cycle progression (43). In the present study, inhibiting miR-223 increased the number of apoptotic cells, possibly as a result of endogenous FBXW7 reducing the activity of cyclin E through an as yet unknown mechanism that ultimately promotes cell apoptosis. Moreover, siRNA was used to directly interfere with the expression of FBXW7, resulting in increased HCT116 cell viability and inhibition of apoptosis. In addition, rescuing FBXW7 after miR-223 transfection produced the opposite result. This indicates that a direct relationship may exist between the proliferation and apoptosis of HCT116 cells and the effect of FBXW7.

miR-223 was upregulated in CRC tissues compared with normal tissues, whereas FBXW7 was downregulated in CRC tissues. The important role of FBXW7 in human cancer suggests that downregulation of FBXW7 through overexpression of miR-223 may become an important indicator of cancer development (44). Dysregulation of miR-223 can attenuate the tumour suppressor activity of FBXW7 during cell transformation (45). Therefore, further investigations of the function of FBXW7 and its downstream pathways in CRC progression are necessary. Blocking the Notch and mTOR pathways has been shown to affect the proliferation of various cancer cells, including endometrial carcinoma, breast cancer and retinoblastoma cells (46,47), indicating that these signalling pathways are involved in the development of these types of cancer. Previous studies have demonstrated that the Notch and NF-κB pathways are involved in cancer cell progression after transcriptionally regulating the expression of miR-223 (31,47). NICD, which is degraded by FBXW7, acts as a transcriptional activator that positively regulates target genes, including Hes-1. Hes-1 directly promotes cell proliferation (48). A recent study concluded that the active status of mTOR, p-mTOR, may be related to cell proliferation (23). In addition, Senoo et al (49) reported that Akt phosphorylation directly mediated Rhonull cell migration and apoptosis. Based on the aforementioned studies and the present results, it may be concluded that inhibition of FBXW7 expression by miR-223 promotes the proliferation and suppresses the apoptosis of HCT116 cells through the Notch and Akt/mTOR pathways. miR-223 has a positive impact on the Notch pathway and Akt/mTOR activation, and whether this effect is mediated directly by miR-223 or indirectly by FBXW7 after miR-223 binding needs to be further clarified.

In summary, the present study demonstrated that upregulated miR-223 binds to the 3′UTR of the FBXW7 gene and inhibits the expression of FBXW7, ultimately promoting the proliferation and preventing the apoptosis of CRC cells through the Notch and Akt/mTOR signalling pathways. Further examination of the upstream molecular mechanism of miR-223 upregulation in CRC cells, and how FBXW7 affects cell invasion and migration, will lead to a better understanding of the occurrence and development of CRC and provide new insight for early screening and diagnosis of CRC.

Supplementary Material

Supporting Data

Acknowledgements

Not applicable.

Funding

This study was funded by the Natural Science Foundation of Hubei Province (grant nos. 2018CFB185, 2018CFB093 and 2017CFB238), the Natural Science Foundation of Hubei Provincial Department of Education (grant nos. Q20192105 and Q20192104), the Faculty Development Grants of Hubei University of Medicine (grant nos. 2016QDJZR03 and 2017QDJZR08), and the Hubei Provincial Training Program of Innovation and Entrepreneurship for Undergraduates (grant nos. S201910929032 and S201913249006).

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

LL and ZL contributed to the design of experiments. ZL, TM, JD and XL conducted the experiments. TM and XL provided reagents. JD and ZL analysed the data. LL and ZL wrote the paper. LL edited the paper. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All procedures performed in the study involving human participants were approved by the ethics committee of Hubei University of Medicine, in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1 

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI

2 

Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI

3 

Zhang K, Song P, Gao J, Li G, Zhao X and Zhang S: Perspectives on a combined test of multi serum biomarkers in China: Towards screening for and diagnosing hepatocellular carcinoma at an earlier stage. Drug Discov Ther. 8:102–109. 2014. View Article : Google Scholar : PubMed/NCBI

4 

Romano M, De Francesco F, Pirozzi G, Gringeri E, Boetto R, Di Domenico M, Zavan B, Ferraro GA and Cillo U: Expression of cancer stem cell biomarkers as a tool for a correct therapeutic approach to hepatocellular carcinoma. Oncoscience. 2:443–456. 2015. View Article : Google Scholar : PubMed/NCBI

5 

Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS, Zhai B, Wan L, Gutierrez A, Lau AW, et al: SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature. 471:104–109. 2011. View Article : Google Scholar : PubMed/NCBI

6 

Yeh CH, Bellon M and Nicot C: FBXW7: A critical tumor suppressor of human cancers. Mol Cancer. 17:1152018. View Article : Google Scholar : PubMed/NCBI

7 

Takeishi S and Nakayama KI: Role of Fbxw7 in the maintenance of normal stem cells and cancer-initiating cells. Brit J Cancer. 111:1054–1059. 2014. View Article : Google Scholar : PubMed/NCBI

8 

Davis RJ, Welcker M and Clurman BE: Tumor suppression by the Fbw7 ubiquitin ligase: Mechanisms and opportunities. Cancer Cell. 26:455–464. 2014. View Article : Google Scholar : PubMed/NCBI

9 

Kawashita Y, Morine Y, Ikemoto T, Saito Y, Iwahashi S, Yamada S, Higashijima J, Imura S, Ogawa H, Yagi T and Shimada M: Loss of Fbxw7 expression is a predictor of recurrence in colorectal liver metastasis. J Hepatobiliary Pancreat Sci. 24:576–583. 2017. View Article : Google Scholar : PubMed/NCBI

10 

Zhao Y, Wang M, Cui C, Zhang L, Liao F, Li H and Wu X: Significance of combined tests of serum golgi glycoprotein 73 and other biomarkers in diagnosis of small primary hepatocellular carcinoma. Cancer Biomark. 15:677–683. 2015. View Article : Google Scholar : PubMed/NCBI

11 

Wang X, Zhang J, Zhou L, Sun W, Zheng ZG, Lu P, Gao Y, Yang XS, Zhang ZC, Tao KS and Dou KF: Fbxw7 regulates hepatocellular carcinoma migration and invasion via Notch1 signaling pathway. Int J Oncol. 47:231–243. 2015. View Article : Google Scholar : PubMed/NCBI

12 

Li G, Luna C, Qiu J, Epstein DL and Gonzalez P: Alterations in microRNA expression in stress-induced cellular senescence. Mech Ageing Dev. 130:731–741. 2009. View Article : Google Scholar : PubMed/NCBI

13 

Ramalinga M, Roy A, Srivastava A, Bhattarai A, Harish V, Suy S, Collins S and Kumar D: MicroRNA-212 negatively regulates starvation induced autophagy in prostate cancer cells by inhibiting SIRT1 and is a modulator of angiogenesis and cellular senescence. Oncotarget. 6:34446–34457. 2015. View Article : Google Scholar : PubMed/NCBI

14 

Hermeking H: MicroRNAs in the p53 network: Micromanagement of tumour suppression. Nat Rev Cancer. 12:613–626. 2012. View Article : Google Scholar : PubMed/NCBI

15 

Welch C, Chen Y and Stallings RL: MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene. 26:5017–5022. 2007. View Article : Google Scholar : PubMed/NCBI

16 

Li R, Wu S, Chen X, Xu H, Teng P and Li W: miR-223/FBW7 axis regulates doxorubicin sensitivity through epithelial mesenchymal transition in non-small cell lung cancer. Am J Transl Res. 8:2512–2524. 2016.PubMed/NCBI

17 

Ibusuki M, Yamamoto Y, Shinriki S, Ando Y and Iwase H: Reduced expression of ubiquitin ligase FBXW7 mRNA is associated with poor prognosis in breast cancer patients. Cancer Sci. 102:439–445. 2011. View Article : Google Scholar : PubMed/NCBI

18 

Yu J, Zhang W, Gao F, Liu YX, Chen ZY, Cheng LY, Xie SF and Zheng SS: FBW7 increases chemosensitivity in hepatocellular carcinoma cells through suppression of epithelial-mesenchymal transition. Hepatobiliary Pancreat Dis Int. 13:184–191. 2014. View Article : Google Scholar : PubMed/NCBI

19 

Ding J, Zhao Z, Song J, Luo B and Huang L: miR-223 promotes the doxorubicin resistance of colorectal cancer cells via regulating epithelial-mesenchymal transition by targeting FBXW7. Acta Biochim Biophys Sin (Shanghai). 50:597–604. 2018. View Article : Google Scholar : PubMed/NCBI

20 

Lu G and Wang J: Dynamic changes in routine blood parameters of a severe COVID-19 case. Clin Chim Acta. 508:98–102. 2020. View Article : Google Scholar : PubMed/NCBI

21 

Gharaibeh L, Elmadany N, Alwosaibai K and Alshaer W: Notch1 in cancer therapy: Possible clinical implications and challenges. Mol Pharmacol. 98:559–576. 2020. View Article : Google Scholar : PubMed/NCBI

22 

Vacca A, Felli MP, Palermo R, Di Mario G, Calce A, Di Giovine M, Frati L, Gulino A and Screpanti I: Notch3 and pre-TCR interaction unveils distinct NF-kappaB pathways in T-cell development and leukemia. EMBO J. 25:1000–1008. 2006. View Article : Google Scholar : PubMed/NCBI

23 

Wu J, Lu AD, Zhang LP, Zuo YX and Jia YP: Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia. Zhonghua Xue Ye Xue Za Zhi. 40:52–57. 2019.(In Chinese). PubMed/NCBI

24 

Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, Marcinkiewicz L, Jiang J, Yang Y, Schmittgen TD, et al: MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res. 69:7569–7576. 2009. View Article : Google Scholar : PubMed/NCBI

25 

Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, Xiang D, Desano JT, Bommer GT, Fan D, et al: MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One. 4:e68162009. View Article : Google Scholar : PubMed/NCBI

26 

Xiao G, Li Y, Wang M, Li X, Qin S, Sun X, Liang R, Zhang B, Du N, Xu C, et al: FBXW7 suppresses epithelial-mesenchymal transition and chemo-resistance of non-small-cell lung cancer cells by targeting snai1 for ubiquitin-dependent degradation. Cell Prolif. 51:e124732018. View Article : Google Scholar : PubMed/NCBI

27 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

28 

Agarwal V, Bell GW, Nam J and Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. eLife,. 4:e050052015. View Article : Google Scholar

29 

Bilinska K, Jakubowska P, Von Bartheld CS and Butowt R: Expression of the SARS-CoV-2 entry proteins, ACE2 and TMPRSS2, in cells of the olfactory epithelium: Identification of cell types and trends with age. ACS Chem Neurosci. 11:1555–1562. 2020. View Article : Google Scholar : PubMed/NCBI

30 

Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ and Fukuda K: Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 289:179–186. 2003. View Article : Google Scholar : PubMed/NCBI

31 

Zhang H, Chen F, He Y, Yi L, Ge C, Shi X, Tang C, Wang D, Wu Y and Nian W: Sensitivity of non-small cell lung cancer to erlotinib is regulated by the Notch/miR-223/FBXW7 pathway. Biosci Rep. 37:BSR201604782017. View Article : Google Scholar : PubMed/NCBI

32 

Sun XF, Sun JP, Hou HT, Li K, Liu X and Ge QX: MicroRNA-27b exerts an oncogenic function by targeting Fbxw7 in human hepatocellular carcinoma. Tumour Biol. 37:15325–15332. 2016. View Article : Google Scholar : PubMed/NCBI

33 

Kurashige J, Watanabe M, Iwatsuki M, Kinoshita K, Saito S, Hiyoshi Y, Kamohara H, Baba Y, Mimori K and Baba H: Overexpression of microRNA-223 regulates the ubiquitin ligase FBXW7 in oesophageal squamous cell carcinoma. Br J Cancer. 106:182–188. 2012. View Article : Google Scholar : PubMed/NCBI

34 

Wang Y, Liu Y, Lu J, Zhang P, Wang Y, Xu Y, Wang Z, Mao JH and Wei G: Rapamycin inhibits FBXW7 loss-induced epithelial-mesenchymal transition and cancer stem cell-like characteristics in colorectal cancer cells. Biochem Biophys Res Commun. 434:352–356. 2013. View Article : Google Scholar : PubMed/NCBI

35 

Iwatsuki M, Mimori K, Ishii H, Yokobori T, Takatsuno Y, Sato T, Toh H, Onoyama I, Nakayama KI, Baba H and Mori M: Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: Clinical significance. Int J Cancer. 126:1828–1837. 2010. View Article : Google Scholar : PubMed/NCBI

36 

Huang Z, Huang D, Ni S, Peng Z, Sheng W and Du X: Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 127:118–126. 2010. View Article : Google Scholar : PubMed/NCBI

37 

Li ZW, Yang YM, Du LT, Dong Z, Wang LL, Zhang X, Zhou XJ, Zheng GX, Qu AL and Wang CX: Overexpression of miR-223 correlates with tumor metastasis and poor prognosis in patients with colorectal cancer. Med Oncol. 31:2562014. View Article : Google Scholar : PubMed/NCBI

38 

Pichler M, Ress AL, Winter E, Stiegelbauer V, Karbiener M, Schwarzenbacher D, Scheideler M, Ivan C, Jahn SW, Kiesslich T, et al: miR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients. Br J Cancer. 110:1614–1621. 2014. View Article : Google Scholar : PubMed/NCBI

39 

Nishida N, Yokobori T, Mimori K, Sudo T, Tanaka F, Shibata K, Ishii H, Doki Y, Kuwano H and Mori M: MicroRNA miR-125b is a prognostic marker in human colorectal cancer. Int J Oncol. 38:1437–1443. 2011.PubMed/NCBI

40 

He D, Huang C, Zhou Q, Liu D, Xiong L, Xiang H, Ma G and Zhang Z: HnRNPK/miR-223/FBXW7 feedback cascade promotes pancreatic cancer cell growth and invasion. Oncotarget. 8:20165–20178. 2017. View Article : Google Scholar : PubMed/NCBI

41 

Liu Z, Liu X, Liu S and Cao Q: Cholesterol promotes the migration and invasion of renal carcinoma cells by regulating the KLF5/miR-27a/FBXW7 pathway. Biochem Biophys Res Commun. 502:69–75. 2018. View Article : Google Scholar : PubMed/NCBI

42 

Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M and Hla T: Expression of cyclooxygenase-1 and −2 in human colorectal cancer. Cancer Res. 55:3785–3789. 1995.PubMed/NCBI

43 

Xu Y, Sengupta T, Kukreja L and Minella AC: MicroRNA-223 regulates cyclin E activity by modulating expression of F-box and WD-40 domain protein 7. J Biol Chem. 285:34439–34446. 2010. View Article : Google Scholar : PubMed/NCBI

44 

Yeh CH, Bellon M, Pancewicz-Wojtkiewicz J and Nicot C: Oncogenic mutations in the FBXW7 gene of adult T-cell leukemia patients. Proc Natl Acad Sci USA. 113:6731–6736. 2016. View Article : Google Scholar : PubMed/NCBI

45 

Hua J, Ding T and Yang L: Dysfunction of microRNA-32 regulates ubiquitin ligase FBXW7 in multiple myeloma disease. Onco Targets Ther. 9:6573–6579. 2016. View Article : Google Scholar : PubMed/NCBI

46 

Thomas MR, Marston L, Rafferty GF, Calvert S, Marlow N, Peacock JL and Greenough A: Respiratory function of very prematurely born infants at follow up: Influence of sex. Arch Dis Child Fetal Neonatal Ed. 91:F197–F201. 2006. View Article : Google Scholar : PubMed/NCBI

47 

Kumar V, Palermo R, Talora C, Campese AF, Checquolo S, Bellavia D, Tottone L, Testa G, Miele E, Indraccolo S, et al: Notch and NF-kB signaling pathways regulate miR-223/FBXW7 axis in T-cell acute lymphoblastic leukemia. Leukemia. 28:2324–2335. 2014. View Article : Google Scholar : PubMed/NCBI

48 

Espinosa L, Cathelin S, D'Altri T, Trimarchi T, Statnikov A, Guiu J, Rodilla V, Inglés-Esteve J, Nomdedeu J, Bellosillo B, et al: The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. Cancer Cell. 18:268–281. 2010. View Article : Google Scholar : PubMed/NCBI

49 

Senoo H, Kamimura Y, Kimura R, Nakajima A, Sawai S, Sesaki H and Iijima M: Phosphorylated Rho-GDP directly activates mTORC2 kinase towards AKT through dimerization with Ras-GTP to regulate cell migration. Nat Cell Biol. 21:867–878. 2019. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

February-2021
Volume 23 Issue 2

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu Z, Ma T, Duan J, Liu X and Liu L: MicroRNA‑223‑induced inhibition of the <em>FBXW7</em> gene affects the proliferation and apoptosis of colorectal cancer cells via the Notch and Akt/mTOR pathways. Mol Med Rep 23: 154, 2021
APA
Liu, Z., Ma, T., Duan, J., Liu, X., & Liu, L. (2021). MicroRNA‑223‑induced inhibition of the <em>FBXW7</em> gene affects the proliferation and apoptosis of colorectal cancer cells via the Notch and Akt/mTOR pathways. Molecular Medicine Reports, 23, 154. https://doi.org/10.3892/mmr.2020.11793
MLA
Liu, Z., Ma, T., Duan, J., Liu, X., Liu, L."MicroRNA‑223‑induced inhibition of the <em>FBXW7</em> gene affects the proliferation and apoptosis of colorectal cancer cells via the Notch and Akt/mTOR pathways". Molecular Medicine Reports 23.2 (2021): 154.
Chicago
Liu, Z., Ma, T., Duan, J., Liu, X., Liu, L."MicroRNA‑223‑induced inhibition of the <em>FBXW7</em> gene affects the proliferation and apoptosis of colorectal cancer cells via the Notch and Akt/mTOR pathways". Molecular Medicine Reports 23, no. 2 (2021): 154. https://doi.org/10.3892/mmr.2020.11793